Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., No. 17-1240 (Fed. Cir. Mar. 28, 2019)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Endo Pharmaceuticals Inc. appeals the district court’s decision holding the claims of U.S. Patent No. 8,808,737 in- eligible under 35 U.S.C. § 101. See Endo Pharms. Inc. v. Actavis Inc. , No. 14-cv-1381-RGA, 2015 WL 7253674 (D. Del. Nov. 17, 2015) (“District Court Op.”), adopting re- port and recommendation , 2015 WL 5580488 (D. Del. Sept. 23, 2015) (“ Magistrate Op. ”). Because the district court incorrectly concluded that the claims at issue are di- rected to a natural law, we reverse.